Literature DB >> 26155828

A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database.

Andrew M Brunner1,2, Gabriela Hobbs1, Marla M Jalbut1, Donna S Neuberg2, Amir T Fathi1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26155828      PMCID： PMC4943877          DOI： 10.3109/10428194.2015.1071490

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  13 in total

1.  Risk of second cancers in chronic myeloproliferative neoplasms.

Authors:  Maria Chiara Susini; Giovanna Masala; Elisabetta Antonioli; Lisa Pieri; Paola Guglielmelli; Domenico Palli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Higher risk of primary cancers after polycythaemia vera and vice versa.

Authors:  Mahdi Fallah; Elham Kharazmi; Jan Sundquist; Kari Hemminki
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

3.  Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.

Authors:  Magnus Björkholm; Asa R Derolf; Malin Hultcrantz; Sigurdur Y Kristinsson; Charlotta Ekstrand; Lynn R Goldin; Björn Andreasson; Gunnar Birgegård; Olle Linder; Claes Malm; Berit Markevärn; Lars Nilsson; Jan Samuelsson; Fredrik Granath; Ola Landgren
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

4.  Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Authors:  Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

5.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

6.  Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience.

Authors:  Jarmila Kissova; Petra Ovesna; Miroslav Penka; Alena Bulikova; Igor Kiss
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

7.  Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

Authors:  Franca Radaelli; Francesco Onida; Francesca G Rossi; Vittorio R Zilioli; Mariangela Colombi; Patrizia Usardi; Rossella Calori; Alberto Zanella
Journal:  Hematology       Date:  2008-08       Impact factor: 2.269

8.  Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.

Authors:  Francesca Palandri; Lucia Catani; Nicoletta Testoni; Emanuela Ottaviani; Nicola Polverelli; Mauro Fiacchini; Antonio De Vivo; Federica Salmi; Alessandro Lucchesi; Michele Baccarani; Nicola Vianelli
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

9.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

Authors:  Omar Abdel-Wahab; Taghi Manshouri; Jay Patel; Kelly Harris; Jinjuan Yao; Cyrus Hedvat; Adriana Heguy; Carlos Bueso-Ramos; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528
View more
  9 in total

1.  Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.

Authors:  Junshik Hong; Ju Hyun Lee; Ja Min Byun; Ji Yun Lee; Youngil Koh; Dong-Yeop Shin; Jeong-Ok Lee; Sang Mee Hwang; Hyoung Soo Choi; Inho Kim; Sung-Soo Yoon; Soo-Mee Bang
Journal:  Blood Adv       Date:  2019-11-26

Review 2.  Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Loretta Nastoupil; Megan Dupuis; Lisa Zhou; Sherry Pierce; Keyur P Patel; Lucia Masarova; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

3.  Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Authors:  Margherita Maffioli; Toni Giorgino; Barbara Mora; Alessandra Iurlo; Elena Elli; Maria Chiara Finazzi; Marianna Caramella; Elisa Rumi; Maria Cristina Carraro; Nicola Polverelli; Mariella D'Adda; Simona Malato; Marianna Rossi; Alfredo Molteni; Alessandro Vismara; Cinzia Sissa; Francesco Spina; Michela Anghilieri; Daniele Cattaneo; Rossella Renso; Marta Bellini; Maria Luisa Pioltelli; Chiara Cavalloni; Daniela Barraco; Raffaella Accetta; Lorenza Bertù; Matteo Giovanni Della Porta; Francesco Passamonti
Journal:  Blood Adv       Date:  2019-11-12

4.  Elevated risk of subsequent malignancies in patients with appendiceal cancer: A population-based analysis.

Authors:  Adil Ayub; Om Parkash; Norberto Santana-Rodríguez; Wissam Raad; Faiz Y Bhora
Journal:  Indian J Gastroenterol       Date:  2016-09-06

5.  Association between myelofibrosis and risk of non-hematologic malignancies: a population-based retrospective cohort study.

Authors:  Walid Saliba; Maria Khudyakova; Elena Mishchenko; Shai Cohen; Gad Rennert; Meir Preis
Journal:  Ann Hematol       Date:  2020-03-10       Impact factor: 3.673

6.  Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Authors:  Marte Karen Brattås; Kyrre Lilleeng; Randi Hovland; Ingvild Jenssen Lægreid; Marta Vorland; Friedemann Leh; Øystein Bruserud; Bjørn Tore Gjertsen; Håkon Reikvam
Journal:  Biomark Res       Date:  2018-11-21

7.  Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Authors:  Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

8.  Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.

Authors:  Rohit Sekhri; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Karlo Huenerbein; Raphael Meixner; Hannah Marchi; Rudolf Wallmann; Christiane Fuchs; Martin Griesshammer; Kai Wille
Journal:  Ann Hematol       Date:  2021-08-31       Impact factor: 3.673

Review 9.  The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.

Authors:  Sung-Yong Kim; Sung Hwa Bae; Soo-Mee Bang; Ki-Seong Eom; Junshik Hong; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Min Kyoung Kim; Soo-Jeong Kim; Yeung-Chul Mun; Seung-Hyun Nam; Jinny Park; Jong-Ho Won; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2020-12-04       Impact factor: 2.884
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.